Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pfizer-BioNTech COVID-19 Vaccine, Bivalent
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Pfizer-BioNTech COVID-19 Vaccine, Bivalent (also known as Comirnaty Bivalent) is an mRNA-based vaccine developed to provide broad protection against COVID-19. It contains two messenger RNA (mRNA) components: tozinameran, which encodes the spike protein of the original SARS-CoV-2 strain, and famtozinameran, which encodes the spike protein of the Omicron BA.4 and BA.5 variants. The mRNA is nucleoside-modified and encapsulated in lipid nanoparticles (LNPs) to facilitate delivery into host cells. Upon intramuscular injection, the mRNA is translated by host cells into spike proteins, which then trigger an adaptive immune response, including the production of neutralizing antibodies and the activation of T-cells. This bivalent formulation was specifically designed to address waning immunity and the increased transmissibility of emerging Omicron subvariants.
- Brand names
- Comirnaty
- Other names
- Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)Tozinameran + Famtozinameran
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Pfizer-BioNTech COVID-19 Vaccine, Bivalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pfizer-BioNTech COVID-19 Vaccine, Bivalent.